Statistical Analysis of Clinical COVID-19 Data: A Concise Overview of Lessons Learned, Common Errors and How to Avoid Them

References

• Wolkewitz M, Sommer H. Evaluating mortality in an intensive care unit requires extended survival models. Crit Care. 2014;18(2):415. doi:10.1186/cc13757
   Web of Science ®Google Scholar
• Wolkewitz M, Schumacher M. Survival biases lead to flawed conclusions in observational treatment studies of influenza patients. J Clin Epidemiol. 2017;84:121–129. doi:10.1016/j.jclinepi.2017.01.00828188897
   PubMed Web of Science ®Google Scholar
• Wolkewitz M, Cooper BS, Bonten MJ, Barnett AG, Schumacher M. Interpreting and comparing risks in the presence of competing events. BMJ. 2014;349(aug21 5):g5060. doi:10.1136/bmj.g506025146097
   PubMed Web of Science ®Google Scholar
• Schumacher M, Allignol A, Beyersmann J, Binder N, Wolkewitz M. Hospital-acquired infections: appropriate statistical treatment is urgently needed. Int J Epidemiol. 2013;42:1502–1508.24038717
   PubMed Web of Science ®Google Scholar
• Wolkewitz M, Harbarth S, Beyersmann J. Daily Chlorhexidine Bathing and Hospital-Acquired Infection. N Engl J Med. 2013;368:2330–2332.
   Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934. doi:10.1001/jamainternmed.2020.0994
   PubMed Web of Science ®Google Scholar
• Lambert J, von Cube M, Biard L, Rieg S, Wolkewitz M. Infectious disease consultation for candidaemia. Lancet Infect Dis. 2020;20(2):164–165. doi:10.1016/S1473-3099(19)30745-5
   Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493. doi:10.1001/jama.2020.8630
   PubMed Web of Science ®Google Scholar
• von Cube M, Schumacher M, Putter H, Timsit J-F, van de Velde C, Wolkewitz M. The population-attributable fraction for time-dependent exposures using dynamic prediction and landmarking. Biometrical J. 2020;62(3):583–597. doi:10.1002/bimj.201800252
   Web of Science ®Google Scholar
• Weber S, von Cube M, Sommer H, Wolkewitz M. Necessity of a competing risk approach in risk factor analysis of central line–associated bloodstream infection. Infect Control Hosp Epidemiol. 2016;37(10):1255–1257. doi:10.1017/ice.2016.16627530258
   PubMed Web of Science ®Google Scholar
• Wolkewitz M. Estimating the risk of ventilator-associated pneumonia as a function of time. Am J Respir Crit Care Med. 2015;192(5):640–641. doi:10.1164/rccm.201502-0282LE26561680
   PubMed Web of Science ®Google Scholar
• Wolkewitz M, Cooper B, Barnett AG, Binder N, Schumacher M. Treatment of hospital-acquired pneumonia. Lancet Infect Dis. 2011;11(10):731–732. doi:10.1016/S1473-3099(11)70262-6
   Web of Science ®Google Scholar
• Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 2013;66(6):648–653. doi:10.1016/j.jclinepi.2012.09.01723415868
   PubMed Web of Science ®Google Scholar
• Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008;168:329–335. doi:10.1093/aje/kwn13518515793
   PubMed Web of Science ®Google Scholar
• Wolkewitz M. Avoidable statistical pitfalls in analyzing length of stay in intensive care units or hospitals. Crit Care. 2014;18(1):408. doi:10.1186/cc1373524602350
   PubMed Web of Science ®Google Scholar
• Wolkewitz M, Allignol A, Harbarth S, de Angelis G, Schumacher M, Beyersmann J. Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias. J Clin Epidemiol. 2012;65(11):1171–1180. doi:10.1016/j.jclinepi.2012.04.00823017635
   PubMed Web of Science ®Google Scholar
• Beyersmann J, Allignol A, Schumacher M. Competing Risks and Multistate Models with R. Springer Science & Business Media; 2011.
   Google Scholar
• Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically Ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis. 2020;70(9):1837–1844. doi:10.1093/cid/ciz54431925415
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-332171076
   PubMed Web of Science ®Google Scholar
• Fine J, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi:10.1080/01621459.1999.10474144
   Web of Science ®Google Scholar
• Poguntke I, Schumacher M, Beyersmann J, Wolkewitz M. Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes. BMC Med Res Methodol. 2018;18(1). doi:10.1186/s12874-018-0535-5
   Web of Science ®Google Scholar
• Sommer H, Timsit J-F, Wolkewitz M; COMBACTE-NET Consortium. Bezlotoxumab and Recurrent Clostridium difficile Infection. N Engl J Med. 2017;376(16):1594. doi:10.1056/NEJMc1702531
   Google Scholar
• Heister T, Wolkewitz M, Kaier K. Determining the attributable costs of clostridium difficile infections when exposure time is lacking: be Wary of “Conditioning on the future”. Infect Control Hosp Epidemiol. 2018;39(6):759–760. doi:10.1017/ice.2018.4229587890
   PubMed Web of Science ®Google Scholar
• Heister T, Wolkewitz M, Kaier K. Estimating the additional costs of surgical site infections: length bias, time-dependent bias, and conditioning on the future. J Hosp Infect. 2018;99(1):103–104. doi:10.1016/j.jhin.2018.02.01229458064
   PubMed Web of Science ®Google Scholar
• Andersen PK, Keiding N. Interpretability and importance of functionals in competing risks and multistate models: interpretability and importance of functionals in competing risks and multistate models. Stat Med. 2012;31(11–12):1074–1088. doi:10.1002/sim.438522081496
   PubMed Web of Science ®Google Scholar
• Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020. doi:10.1016/S0140-6736(20)31180-6
   Web of Science ®Google Scholar
• Wynants L, Van Calster B, Bonten MM, et al. Systematic review and critical appraisal of prediction models for diagnosis and prognosis of COVID-19 infection. medRxiv. 2020.
   Google Scholar
• Glasziou PP, Sanders S, Hoffmann T. Waste in Covid-19 Research. British Medical Journal Publishing Group; 2020.
   Google Scholar